Brand name authorized in: Austria Ireland Lithuania United States
The drug OMIDRIA contains a combination of these active pharmaceutical ingredients (APIs):
Phenylephrine is a sympathomimetic agent with mainly direct effects on adrenergic receptors. It has predominantly alpha adrenergic activity and is without stimulating effects on the central nervous system. The sympathomimetic effect of phenylephrine produces vasoconstriction which in turn relieves nasal congestion.
Ketorolac is a non-steroidal anti-inflammatory agent demonstrating analgesic and anti-inflammatory activity. Ketorolac inhibits the cyclo-oxygenase enzyme essential for biosynthesis of prostaglandins. Ketorolac has been shown to reduce prostaglandin levels in the aqueous humour after topical ophthalmic administration.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
Below package inserts are available for further reading:
This drug has been assigned below unique identifiers within the countries it is being marketed: